GlaxoSmithKline Will Get $500M In CureVac-Pfizer Patent Deal

British pharmaceutical company GlaxoSmithKline said Friday it stands to make up to $500 million from settlements between German biotech companies CureVac and BioNTech after their legal disputes were squashed by a...

Already a subscriber? Click here to view full article